<303A> Visumo 2340 -700

Limit down. After reaching an all-time high in the morning, there was a shift to selling pressure from a sense of buyer fatigue. Visumo was newly listed on December 26 last year, debuting at 1,036 yen, which is 34.5% higher than the public offering price of 770 yen. Since then, it has recorded limit up day after day, surging to 3,110 yen in the morning of the 8th, nearly three times its initial price. The Financial Estimates for the fiscal year ending March 2025 forecast operating profit to increase by 291.8% year-on-year to 0.073 billion yen, leading to an Inflow of investment funds; however, there appears to be rising caution regarding high prices.

<3967> Ertes 777 +100

It hit the upper limit. The shareholder benefit system has been expanded, and it has been announced that shareholders who hold more than 800 shares for six months will be given a QUO card worth 0.01 million yen. The purpose is to encourage continuous long-term holding to strengthen IR activities. The record date is the end of August and the end of February, and it will be implemented from the end of August 2025. Furthermore, Ertes disclosed on November 18 last year that as a 20th-anniversary benefit for shareholders holding more than 800 shares (with no holding period requirement), a QUO card worth 0.02 million yen will be presented at the end of February.

<269A> Sapeet 3860 +700

It reached the limit up. The company announced on the morning of the 7th that their AI posture analysis system 'Karti Shisei Karte' will begin API integration with the next-generation smart mirror 'MIRRORFIT.' offered by MirrorFit (Meguro, Tokyo) starting in mid-January, and it continues to be viewed as a Buy material. Shisei Karte is a system that allows AI posture analysis by simply taking a few full-body photos with a Smart Phone, and it has been implemented in osteopathic clinics and fitness gyms.

<5247> BTM 2551 +500

After a 6-day decline, there was a rebound and a stop-high. Hokuhoku Financial Group <8377> announced the signing of a contract related to business matching with Hokuriku Bank (Toyama City), and they have started business matching services aimed at promoting DX for small and medium-sized enterprises in the three Hokuriku prefectures of Toyama, Ishikawa, and Fukui. Among the consultations about DX and other matters from local companies to Hokuriku Bank, those that require high expertise will be referred to BTM, which will support local companies.

＜4592＞ Sanbio 770 +19

Significant rebound. It has been announced that a paper demonstrating that the company's main development product, human bone marrow-derived processed mesenchymal stem cells "Vandefitem Cell (SB623)", improves cortical excitability in rats with local brain ischemia has been published in the American scientific journal "Molecular Therapy". According to the paper, it was found that the transplantation of Vandefitem Cell alleviates the hyperexcitability of the cerebral cortex caused by brain ischemia and restores normal brain function.

＜4591＞ Ribomic 106 +23

Significant rebound. It has been announced that a successful creation and development of an "anti-neutrophil elastase aptamer," which is a candidate for Cosmetic raw materials, has been achieved, and a patent application has been submitted to the Japan Patent Office in collaboration with Mitsubishi Corporation Life Sciences (Chiyoda, Tokyo), a subsidiary of Mitsubishi Corporation. Neutrophil elastase is a protein-degrading enzyme secreted by neutrophils, which are important cells in the immune system. In the future, efforts will be made to consider practical applications and aim to expand growth areas such as the Cosmetic market.